Clinical pharmacology is the science concerned with studying the effects of drugs and medicines in humans and their optimal clinical use in patients. It brings together scientific knowledge about medicines with the practical realities of patient care. While a medicine may have a known mechanism of action and established indications, its effects can vary considerably between individuals. Clinical pharmacology seeks to understand these differences and use this knowledge to optimise therapy.
At its core, clinical pharmacology promotes the rational use of medicines. This means ensuring that patients receive the most appropriate medicine, at an appropriate dose, for the appropriate indication, while carefully considering the expected benefits and potential risks. The aim is to maximise therapeutic benefit, minimise adverse effects, and improve overall patient outcomes.
The effects of medicines are not determined by the drug alone. They are influenced by several patient-related factors, including age, body size, kidney and liver function, genetics, concurrent medications, disease states, and individual variability in drug response. Clinical pharmacology helps healthcare professionals understand how these factors influence the way a medicine behaves in the body and the response it produces.
Clinical pharmacologists therefore play an important role in bridging the gap between science and the practice of medicine. They contribute to the research, development, evaluation, regulation, and clinical use of medicines. Their work extends from understanding how new medicines behave in humans during drug development to helping optimise the use of established medicines in everyday clinical practice.
Recently, a patient receiving tacrolimus was referred for evaluation after developing symptoms suggestive of possible drug toxicity. The clinical presentation raised concern that the patient's symptoms could be related to medication exposure, prompting a detailed review of the treatment history.
Tacrolimus is an immunosuppressive medicine with a narrow therapeutic index. This means that relatively small changes in drug exposure can potentially lead to clinically significant toxicity or inadequate immunosuppression. Therefore, careful therapeutic drug monitoring is an important component of its clinical use.
The referral was initially prompted by the patient's symptoms of toxicity. However, identifying the underlying cause required looking beyond the symptoms alone.
A detailed medication history was obtained.
During the review, it was discovered that the patient had recently taken a single dose of fluconazole.
At first glance, a single dose may appear clinically insignificant. However, from a clinical pharmacology perspective, this information was important.
Tacrolimus is extensively metabolised primarily through the CYP3A enzyme system. Fluconazole can inhibit CYP3A-mediated metabolism, reducing the metabolism of tacrolimus and potentially increasing tacrolimus exposure.
This raised an important possibility:
Could the recent fluconazole exposure have contributed to increased tacrolimus concentrations and the patient's symptoms of toxicity?
Based on the clinical presentation and the possibility of a clinically significant drug interaction, therapeutic drug monitoring (TDM) of tacrolimus was requested.
The tacrolimus concentration was found to be elevated above the intended therapeutic range.
This provided an important explanation for the patient's clinical presentation.
The referral for suspected toxicity had therefore led to a systematic medication review, identification of a potential drug interaction, and confirmation of increased drug exposure through therapeutic drug monitoring.
Going forward, we will explore more interesting cases, concepts, and developments from the world of clinical pharmacology. Through EvidenceRx, we hope to discuss real-world medication-related problems, therapeutic drug monitoring, drug interactions, adverse drug reactions, antimicrobial stewardship, emerging concepts, and new medicines.
The aim is to move beyond simply defining pharmacological concepts and instead ask meaningful questions:
Why did this happen?
What pharmacological mechanism explains it?
How could it affect patient care?
What can we learn from it?
Through cases, concepts, evidence, and discussion, we hope to explore the fascinating relationship between medicines, science, and patient care—one clinical question at a time.